KMT Hepatech is expanding its services with the PXB-Mouse – a humanized liver chimeric mouse model for drug discovery and development – following a strategic investment from PhoenixBio late last year.
It is an “exciting time in drug discovery,” says Charles River CSO as the company expands its CRISPR/Cas9 service offering with a license from ERS Genomics.
AMRI’s SSCI has announced the availability of in vitro bioequivalence testing services, as more products entering the market require laboratory-based testing.
EAG Laboratories has added dermal absorption studies to its GLP-compliant testing services suite, as part of the company’s plan to continue expanding its capabilities.
Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
Sensors, computer vision, machine learning, and cloud computing are enabling preclinical researchers to conduct higher quality studies in a shorter period of time.
Cyprotex has expanded its toxicology offering with a new in silico technology it claims will reduce preclinical costs and cut the number of animal studies required.
Preclinical CRO Agilux has increased capacity at its research facility in Massachusetts, US, citing customer desire for faster in vivo studies as the driver for the investment.
Caliper Life sciences has entered into a definitive merger agreement with Cambridge Research & Instrumentation (CRi) to boost its discovery biomarker and personalised medicine development offering.
